Internal Medicine

ImmunoGen Inc. announced it grants Biotest AG exclusive rights to use ImmunoGen’s Tumor-Activated Prodrug (TAP) technology with antibodies targeting an undisclosed target to develop novel anticancer therapeutics.

KineMed and Organon announced today that they have signed an agreement to discover new applications for multiple drug candidates.

Data management company Unleashed Informatics recently introduced its Unleashed Global Services arm to complement its bioinformatics software and hardware offerings.

Dana Farber Cancer Institute (DFCI), 454 Life Sciences and other research centers performed detailed sequencing experiments to identify subtle but significant cancer-associated mutations.

Metabolex announced a strategic agreement with Ortho-McNeil to collaborate on the development and commercialization of compounds targeting metabolic disorders.

Because of their pivotal role in so many cell growth functions, microtubules are popular targets for anti-cancer drugs. Unfortunately, drug resistance and toxicity can be significant problems.

In cancer treatment, the correlation of pharmacogenomics and drug efficacy requires genetic sampling directly from tumors, but this presents difficulties in terms of invasiveness and sample preparation.

Biopharmaceutical company Tranzyme Pharma

MDS Pharma Services

Solexa Inc. announced a collaboration with Invitrogen on its Genome Analysis System that reduces the cost of resequencing human genomes to about $100,000.

Cytopia Ltd. recently announced the signing of a global license and research and development collaboration with Novartis to develop orally active, small-molecule therapeutics targeting the JAK3 kinase for the prevention of transplant rejection and the treatment of autoimmune diseases such as rheumatoid arthritis.

BioImagene recently closed its acquisition of Pittsburgh-based tissue image analysis company TissueInformatics from Icoria, a business unit of Clinical Data Inc.